Medical device fundraising runs on a clinical and regulatory cadence, not a software one. Rounds are paced against 510(k), De Novo or PMA submissions, CE-mark transition under EU MDR, first commercial launches and the reimbursement coverage decisions that determine volume. Investors underwrite on installed-base trajectory, consumable pull-through, gross margin durability and the realistic path to Medicare and commercial coverage, with stage-up valuations tied to specific regulatory or reimbursement events.

The capital pools active in device venture are well defined. Life-sciences specialists with medtech practices - OrbiMed, Versant - lead surgical, interventional and implantable rounds; healthcare-focused funds like F-Prime and GV cover monitoring and wearables and the diagnostics-adjacent categories; and the corporate venture arms attached to the major strategics participate where the technology maps to an existing franchise - Medtronic, Stryker, J&J MedTech, Boston Scientific, Abbott, BD and Edwards Lifesciences all run active CVC programmes. Flow has direct relationships across this investor and strategic set and maps by device category and recent lead history.

Flow has experience running VC fundraising processes for medical device companies across diagnostics and IVD platforms, surgical and interventional devices, monitoring and wearables, implantables and capital equipment and reagent platforms. Our extensive investor network spans early-stage seed funds, growth-stage investors, and strategic and corporate VC arms.